Stryker Corporation (SYK)
NYSE:SYK
Want to see SYK full AI Analyst Report?
SYK Stock Chart & Stats
$338.38
$6.61(1.86%)
At close: 4:00 PM EST
$338.38
$6.61(1.86%)
Day’s Range― - ―
52-Week Range$319.32 - $404.87
Previous CloseN/A
Volume378.36K
Average Volume (3M)2.08M
Market Cap
$130.69B
Enterprise Value$140.34B
Total Cash (Recent Filing)$4.10B
Total Debt (Recent Filing)$14.86B
Price to Earnings (P/E)41.4
Beta0.68
Next Earnings
Apr 30, 2026EPS Estimate
2.98Next Dividend Ex-DateN/A
Dividend Yield0.95%
Share Statistics
EPS (TTM)4.47
Shares Outstanding382,984,250
10 Day Avg. Volume1,588,981
30 Day Avg. Volume2,084,095
Financial Highlights & Ratios
PEG Ratio5.16
Price to Book (P/B)5.99
Price to Sales (P/S)5.35
P/FCF Ratio31.36
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue5.59
Enterprise Value/Gross Profit8.79
Enterprise Value/Ebitda25.13
Forecast
1Y Price Target
$425.10Price Target Upside25.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
EPS Forecast (FY)15
Revenue Forecast (FY)$27.33B
Bulls Say, Bears Say
Bulls Say
AcquisitionStryker's acquisition of Amplitude Vascular adds a novel peripheral revascularization technology and creates a pathway to expand into coronary vascular markets pending regulatory clearance.
Commercial Execution And Financial PerformanceA scalable sales organization, healthy order backlog, and stronger-than-expected revenue and profit growth support expectations for continued sales momentum and margin expansion.
Robotics And Product InnovationNew handheld and shoulder robotic systems are positioned to lower adoption barriers, broaden surgical applications, and increase procedure penetration across existing franchises.
Bears Say
Commercial Cost PressureExpansion into coronary indications will likely require hiring additional sales representatives, increasing commercial costs and potentially compressing near-term margins.
Cybersecurity DisruptionA cybersecurity incident caused a material operational disruption and a near-term hit to results, with some connected systems taken offline and cases converted from robotic to non-robotic procedures.
Market And Valuation RiskShares trading at a premium versus large-cap peers combined with softer hospital capital spending in some regions create valuation and execution risk if growth weakens.
Stryker News
SYK FAQ
What was Stryker Corporation’s price range in the past 12 months?
Stryker Corporation lowest stock price was $319.32 and its highest was $404.87 in the past 12 months.
What is Stryker Corporation’s market cap?
Stryker Corporation’s market cap is $130.69B.
When is Stryker Corporation’s upcoming earnings report date?
Stryker Corporation’s upcoming earnings report date is Apr 30, 2026 which is in 13 days.
How were Stryker Corporation’s earnings last quarter?
Stryker Corporation released its earnings results on Jan 29, 2026. The company reported $4.47 earnings per share for the quarter, beating the consensus estimate of $4.396 by $0.074.
Is Stryker Corporation overvalued?
According to Wall Street analysts Stryker Corporation’s price is currently Undervalued.
Does Stryker Corporation pay dividends?
Stryker Corporation pays a Quarterly dividend of $0.84 which represents an annual dividend yield of 0.95%. See more information on Stryker Corporation dividends here
What is Stryker Corporation’s EPS estimate?
Stryker Corporation’s EPS estimate is 2.98.
How many shares outstanding does Stryker Corporation have?
Stryker Corporation has 382,984,250 shares outstanding.
What happened to Stryker Corporation’s price movement after its last earnings report?
Stryker Corporation reported an EPS of $4.47 in its last earnings report, beating expectations of $4.396. Following the earnings report the stock price went up 4.307%.
Which hedge fund is a major shareholder of Stryker Corporation?
Currently, no hedge funds are holding shares in SYK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Stryker Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$425.10 (25.63% Upside)
$425.10 (25.63% Upside)
Blogger Sentiment
Bullish
SYK Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 112.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $181.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.8%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-0.65%
12-Months-Change
Fundamentals
Return on Equity
15.04%
Trailing 12-Months
Asset Growth
11.34%
Trailing 12-Months
Company Description
Stryker Corporation
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.
SYK Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized broad-based revenue and earnings strength, record robotics momentum (Mako 4 and installed base >3,000), strong cash generation, and continued margin expansion, while also acknowledging manageable near-term headwinds including tariffs (~$400M in 2026), higher interest expense, competitive pressure in parts of vascular, and some regional capital softness. Guidance for 2026 is constructive (8.0%–9.5% organic growth and $14.90–$15.10 adjusted EPS) and management highlighted operational levers and M&A firepower to support growth.View all SYK earnings summariesSYK Net sales Breakdown
62.30% MedSurg and Neurotechnology
37.70% Orthopaedics and Spine
SYK Stock 12 Month Forecast
Average Price Target
$425.10
▲(25.63% Upside)
Technical Analysis
Abbott Laboratories
―
Boston Scientific
―
Edwards Lifesciences
―
Medtronic
―
Zimmer Biomet Holdings
―
Ownership Overview
4.09% Insiders
19.77% Mutual Funds
0.30% Other Institutional Investors
56.74% Public Companies and Individual Investors